Piperidine and morphonline derivatives and their use as therapeutic
agents
    16.
    发明授权
    Piperidine and morphonline derivatives and their use as therapeutic agents 失效
    哌啶和吗啉衍生物及其作为治疗剂的用途

    公开(公告)号:US5830892A

    公开(公告)日:1998-11-03

    申请号:US981294

    申请日:1997-12-18

    CPC分类号: C07D401/14

    摘要: The present invention provides compounds of formula (I), wherein R.sup.1 is a 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and sulphur, which group is optionally substituted; R.sup.2 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, OCF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substitued by C.sub.1-4 alkoxy, where R.sup.a and R.sup.a R.sup.b each independently represent hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 -alkoxy substituted by C.sub.1-4 alkoxy or CF.sub.3 ; R.sup.4, R.sup.5, R.sup.6, R.sup.9a, R.sup.9b, A, X and Y are as defined in the specification; and m is zero or , and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and pos therpetic neuralgia.

    摘要翻译: PCT No.PCT / GB96 / 01478 Sec。 371 1997年12月18日第 102(e)1997年12月18日PCT PCT 1996年6月20日PCT公布。 公开号WO97 / 01553 日期1997年1月16日本发明提供式(I)化合物,其中R 1是含有1,2,3或4个选自氮,氧和硫的杂原子的5或6元芳族杂环基,该基团任选地 取代 R2是氢,卤素,C1-6烷基,C1-6烷氧基,CF3,OCF3,NO2,CN,SRa,SORa,SO2Ra,CO2Ra,CONRaRb,C2-6烯基,C2-6炔基或C1-4烷氧基取代的C1-4烷基, Ra和RaRb各自独立地表示氢或C 1-4烷基; R3是氢,卤素,C1-6烷基,被C1-4烷氧基或CF3取代的C1-6烷氧基; R4,R5,R6,R9a,R9b,A,X和Y如说明书中所定义; 并且m为0或其药学上可接受的盐和前药。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和炎症性神经痛。